A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients

A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients

Abstract Olanzapine has exhibited efficacy as an antiemetic agent when used with 5-HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists for patients receiving highly emetogenic chemotherapy. In addition, several studies have reported the efficacy or safety of olanzapine in patients...

Full description

Bibliographic Details
Main Authors: Junichi Nishimura, Akiko Hasegawa, Toshihiro Kudo, Tomoyuki Otsuka, Masayoshi Yasui, Chu Matsuda, Naotsugu Haraguchi, Hajime Ushigome, Nozomu Nakai, Tomoki Abe, Hisashi Hara, Naoki Shinno, Kei Asukai, Shinichiro Hasegawa, Daisaku Yamada, Keijiro Sugimura, Kazuyoshi Yamamoto, Hiroshi Wada, Hidenori Takahashi, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue
Format: Article
Language:English
Published: Nature Portfolio 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84225-6

Internet

https://doi.org/10.1038/s41598-021-84225-6

Similar Items